自由脂肪酸受容体4のアゴニストは,マウスとヒトの島において異なるメカニズムでインスリン分泌を刺激する
bioRxiv : the preprint server for biology
|September 2, 2025
まとめ
自由脂肪酸受容体FFAR4の活性化により,インスリン分泌が増加します. マウスでは,ソマトスタチン阻害によって間接的に発生するが,ヒトの小島は,直接のベータ細胞効果を示し,FFAR4治療の種の違いを強調する.
科学分野:
- 内分泌学
- 分子薬理学
- 細胞生物学
背景:
- 自由脂肪酸受容体4 (FFAR4) は,臓の小島に存在する.
- FFAR4の活性化はインスリンとソマトスタチン (SST) の分泌に影響する.
研究 の 目的:
- マウスとヒトの小島におけるホルモン分泌に対するFFAR4の作用のメカニズムを解明する.
- FFAR4シグナル伝達経路の種別差異を調査する.
主な方法:
- マウスとヒトの小島にFFAR4アゴニスト化合物A (Cpd A) を利用し,遺伝子組み換えモデル (デルタ細胞切除,SST切除,Gαz切除) を含む.
- 精製されたマウスベータ細胞とデルタ細胞,ヒトEndoC-bH5細胞とヒト小島を調べた.
- 特定の細胞型と小島におけるCpd Aに対するCa++ダイナミクスの測定
主要な成果:
- ネズミでは,Cpd Aのインスリン誘発作用はデルタ細胞除去とSST欠乏の小島で廃止され,精製されたβ細胞では存在しない.
- Gαzの消去は,Cpd AによるSST分泌の抑制を弱めたが,インスリン増強はしなかった.
- マウスのデルタ細胞におけるCpd AのCa++トランジエントの減少は,Gαz欠乏した小島で失われる.
- ヒトの小島では,FFAR4の活性化により,SSTとは無関係にインスリン分泌とCa++トランジタが増加した.
- ヒト EndoC- bH5 細胞における直接増強されたインスリン分泌.
結論:
- FFAR4によるマウス小島インスリン刺激は間接的であり,Gαz結合SST阻害によって媒介される.
- FFAR4の活性化によるヒト小島インスリン放出は,ベータ細胞による直接的な効果である.
- メタボリック疾患を標的とした治療の開発に不可欠なFFAR4シグナル伝達における種別による有意な差異を特定した.
関連する概念動画
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Insulin Secretory Vesicles
5.4K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.4K
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252


